{
    "Trade/Device Name(s)": [
        "Access hsTnI"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K172787",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121214"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MMI"
    ],
    "Summary Letter Date": "May 4, 2018",
    "Summary Letter Received Date": "May 7, 2018",
    "Submission Date": "June 12, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Cardiac troponin I (cTnI)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Access 2 Immunoassay System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access hsTnI chemiluminescent immunoassay for quantitative determination of cardiac troponin I using the Access 2 Immunoassay System",
    "Indications for Use Summary": "Aids in the diagnosis of myocardial infarction (MI) by quantitatively measuring cardiac troponin I (cTnI) levels in human serum and plasma using the Access 2 Immunoassay System",
    "fda_folder": "Clinical Chemistry"
}